

ALKERMES INC  
Form 8-K  
April 28, 2008

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K  
CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of report (Date of earliest event reported): April 18, 2008  
ALKERMES, INC.  
(Exact Name of Registrant as Specified in its Charter)**

**PENNSYLVANIA**  
(State or Other Jurisdiction of  
Incorporation)

**1-14131**  
(Commission  
File Number)

**23-2472830**  
(I.R.S. Employer  
Identification No.)

***88 Sidney Street***  
***Cambridge, Massachusetts***  
(Address of principal executive offices)

**02139**  
(Zip Code)

Registrant's telephone number, including area code: **(617) 494-0171**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**TABLE OF CONTENTS**

Item 7.01 Regulation FD Disclosure  
SIGNATURE

---

**Table of Contents**

**Item 7.01 Regulation FD Disclosure**

On April 18, 2008, Alkermes, Inc. ( Alkermes ) orally confirmed to Indevus Pharmaceuticals, Inc. and then reconfirmed on April 28, 2008 in writing that the Feasibility Agreement dated as of February 4, 2005, which related to the development of an inhaled formulation of trospium chloride ( ALKS 27 ) for the treatment of chronic obstructive pulmonary disease, had terminated in accordance with its terms.

All patent rights related to ALKS 27 are owned by Alkermes.

Alkermes intends to independently continue the development and commercialization of an inhaled trospium product based on its proprietary AIR<sup>®</sup> pulmonary technology.

---

**Table of Contents**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALKERMES, INC.**

Date: April 28, 2008

By: /s/ James M. Frates  
James M. Frates  
Senior Vice President, Chief Financial  
Officer and Treasurer